Drug news
FDA approves FluBlok vaccine ( Protein Sciences) for Influenza
The FDA announced on 16 January 2013 that it has approved Flublok, the first trivalent influenza vaccine made using an insect virus (baculovirus) expression system and recombinant DNA technology. Flublok is approved for the prevention of seasonal influenza in people 18 through 49 years of age. As it does with all influenza vaccines, the FDA will evaluate Flublok annually prior to use by the public each flu season.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins